A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
The signs and symptoms of the AIDS Dementia Complex can be alleviated by zidovudine (ZDV). However, ZDV therapy has been associated with significant toxicities, particularly bone marrow suppression. The efficacy of ZDV appears to decrease during the second and third years of therapy. It is not known whether this reflects cumulative toxicity. In addition, the efficacy of other antiretroviral agents remains uncertain. Hence, adjunctive therapy for cognitive and motor symptoms of AIDS is important.
Patients will be randomized to one of the following 2 arms:
Arm 1 receives memantine plus conc...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- You may be eligible for this study if you:
- • Are HIV positive.
- • Have been diagnosed with AIDS dementia complex (ADC).
- • Have an estimated IQ of at least 70 (before the onset of ADC) or the ability to read at a 6th grade level.
- • Have impaired mental skills.
- • Are age18 or older.
- • Exclusion Criteria
- You will not be eligible for this study if you:
- • Have a history of a neurologic disease unrelated to HIV infection.
- • Have a history of chronic seizures or head injuries.
- • Have a history of central nervous system infections.
- • Have certain cancers.
- • Have any psychiatric illness.
- • Have an active AIDS-defining opportunistic infection.
- • Are pregnant or breast-feeding.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
San Francisco, California, United States
Miami, Florida, United States
Honolulu, Hawaii, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Omaha, Nebraska, United States
Buffalo, New York, United States
New York, New York, United States
Rochester, New York, United States
Philadelphia, Pennsylvania, United States
Seattle, Washington, United States
St. Louis, Missouri, United States
Honolulu, Hawaii, United States
Lexington, Kentucky, United States
New York, New York, United States
New York, New York, United States
Patients applied
Trial Officials
Bradford Navia
Study Chair
Richard Price
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials